Figure 4.
Emicizumab activity in FVIII-deficient mice. (A) FVIII-deficient mice were given incomplete combinations of emicizumab (3 mg/kg given 24 hours before tail amputation), FIX (100 U/kg given 5 minutes before tail amputation), and FX (100 U/kg given 5 minutes before tail amputation), each time with 1 of the 3 proteins missing. The tail bleeding was executed as described in the Figure 3 legend. Data represent individual mice. (B) FVIII-deficient mice were given emicizumab (0-10 mg/kg given 24 hours before tail amputation) and FIX/FX (both 100 U/kg given 5 minutes before tail amputation). Presented is blood loss over 30 minutes vs emicizumab dose. Data represent individual mice. Data for 0 mg/kg emicizumab are similar as those presented in Figure 3A. (C) Emicizumab (5 mg/kg) was given to FVIII-deficient mice in combination with different doses of FIX and FX (25-200 U/kg) prior to tail bleeding as described for panel B. Data for 0 mg/kg emicizumab are similar to those presented in Figure 3A and data for 100 U FIX-FX/kg are similar to those presented in panel B. Statistical analysis was performed via 1-way ANOVA with Dunnett multiple comparison.

Emicizumab activity in FVIII-deficient mice. (A) FVIII-deficient mice were given incomplete combinations of emicizumab (3 mg/kg given 24 hours before tail amputation), FIX (100 U/kg given 5 minutes before tail amputation), and FX (100 U/kg given 5 minutes before tail amputation), each time with 1 of the 3 proteins missing. The tail bleeding was executed as described in the Figure 3 legend. Data represent individual mice. (B) FVIII-deficient mice were given emicizumab (0-10 mg/kg given 24 hours before tail amputation) and FIX/FX (both 100 U/kg given 5 minutes before tail amputation). Presented is blood loss over 30 minutes vs emicizumab dose. Data represent individual mice. Data for 0 mg/kg emicizumab are similar as those presented in Figure 3A. (C) Emicizumab (5 mg/kg) was given to FVIII-deficient mice in combination with different doses of FIX and FX (25-200 U/kg) prior to tail bleeding as described for panel B. Data for 0 mg/kg emicizumab are similar to those presented in Figure 3A and data for 100 U FIX-FX/kg are similar to those presented in panel B. Statistical analysis was performed via 1-way ANOVA with Dunnett multiple comparison.

Close Modal

or Create an Account

Close Modal
Close Modal